Logo image of ARGX.BR

ARGENX SE (ARGX.BR) Stock Price, Quote, News and Overview

EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR

472.8  0 (0%)

ARGX.BR Quote, Performance and Key Statistics

ARGENX SE

EBR:ARGX (6/18/2025, 5:36:15 PM)

472.8

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High658
52 Week Low394.2
Market Cap28.87B
Shares61.06M
Float60.97M
Yearly DividendN/A
Dividend YieldN/A
PE102.34
Fwd PE26.92
Earnings (Next)07-31 2025-07-31/bmo
IPO07-10 2014-07-10


ARGX.BR short term performance overview.The bars show the price performance of ARGX.BR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ARGX.BR long term performance overview.The bars show the price performance of ARGX.BR in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of ARGX.BR is 472.8 EUR. In the past month the price decreased by -7.94%. In the past year, price increased by 27.17%.

ARGENX SE / ARGX Daily stock chart

ARGX.BR Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1ABBV.MI ABBVIE INC 18.69 293.65B
4AB.DE ABBVIE INC 18.09 283.68B
AMG.DE AMGEN INC 14.23 137.38B
GIS.DE GILEAD SCIENCES INC 14.11 117.44B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 99.51B
1REGN.MI REGENERON PHARMACEUTICALS 11.98 49.56B
22UA.DE BIONTECH SE-ADR N/A 21.80B
IDP.DE BIOGEN INC 8.15 16.35B
1EXEL.MI EXELIXIS INC 18.93 9.81B
1MRNA.MI MODERNA INC N/A 8.71B
0QF.DE MODERNA INC N/A 8.67B
GLPG.AS GALAPAGOS NV N/A 1.62B

About ARGX.BR

Company Profile

ARGX logo image argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Company Info

ARGENX SE

Laarderhoogtweg 25

Amsterdam NOORD-HOLLAND NL

Employees: 1599

ARGX Company Website

ARGX Investor Relations

Phone: 31763030

ARGENX SE / ARGX.BR FAQ

What is the stock price of ARGENX SE today?

The current stock price of ARGX.BR is 472.8 EUR.


What is the ticker symbol for ARGENX SE stock?

The exchange symbol of ARGENX SE is ARGX and it is listed on the Euronext Brussels exchange.


On which exchange is ARGX.BR stock listed?

ARGX.BR stock is listed on the Euronext Brussels exchange.


What is the price forecast or stock price prediction for ARGENX SE stock?

26 analysts have analysed ARGX.BR and the average price target is 686.38 EUR. This implies a price increase of 45.17% is expected in the next year compared to the current price of 472.8. Check the ARGENX SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARGENX SE worth?

ARGENX SE (ARGX.BR) has a market capitalization of 28.87B EUR. This makes ARGX.BR a Large Cap stock.


How many employees does ARGENX SE have?

ARGENX SE (ARGX.BR) currently has 1599 employees.


What are the support and resistance levels for ARGENX SE (ARGX.BR) stock?

ARGENX SE (ARGX.BR) has a support level at 472.79 and a resistance level at 497.88. Check the full technical report for a detailed analysis of ARGX.BR support and resistance levels.


Is ARGENX SE (ARGX.BR) expected to grow?

The Revenue of ARGENX SE (ARGX.BR) is expected to grow by 64.81% in the next year. Check the estimates tab for more information on the ARGX.BR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARGENX SE (ARGX.BR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARGENX SE (ARGX.BR) stock pay dividends?

ARGX.BR does not pay a dividend.


When does ARGENX SE (ARGX.BR) report earnings?

ARGENX SE (ARGX.BR) will report earnings on 2025-07-31, before the market open.


What is the Price/Earnings (PE) ratio of ARGENX SE (ARGX.BR)?

The PE ratio for ARGENX SE (ARGX.BR) is 102.34. This is based on the reported non-GAAP earnings per share of 4.62 and the current share price of 472.8 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.BR.


ARGX.BR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR turns out to be only a medium performer in the overall market: it outperformed 67.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARGX.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ARGX.BR. ARGX.BR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARGX.BR Financial Highlights

Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 4.62. The EPS increased by 194.52% compared to the year before.


Industry RankSector Rank
PM (TTM) 38.01%
ROA 13.42%
ROE 15.14%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%348.08%
Sales Q2Q%95.72%
EPS 1Y (TTM)194.52%
Revenue 1Y (TTM)31.82%

ARGX.BR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ARGX.BR. The Buy consensus is the average rating of analysts ratings from 26 analysts.

For the next year, analysts expect an EPS growth of 576.65% and a revenue growth 64.81% for ARGX.BR


Ownership
Inst Owners39.98%
Ins Owners0.12%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.62
Price Target686.38 (45.17%)
EPS Next Y576.65%
Revenue Next Year64.81%